{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:27:24Z","timestamp":1784654844778,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Jingzhou Central Hospital","award":["201306066"],"award-info":[{"award-number":["201306066"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bbrc.2017.08.097","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T10:45:09Z","timestamp":1503657909000},"page":"373-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage"],"prefix":"10.1016","volume":"492","author":[{"given":"Min","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youkong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2017.08.097_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H","article-title":"Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2","volume":"80","author":"Bukowski","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2017.08.097_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/1477-3163.127638","article-title":"Targeted therapy for renal cell carcinoma: the next lap","volume":"13","author":"Kanesvaran","year":"2014","journal-title":"J.\u00a0Carcinog."},{"key":"10.1016\/j.bbrc.2017.08.097_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbrc.2017.08.097_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2017.08.097_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/bbrc.1999.0580","article-title":"Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells","volume":"258","author":"Miranda","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2017.08.097_bib6","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.18632\/oncotarget.4401","article-title":"Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells","volume":"6","author":"De Luca","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2017.08.097_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002280050131","article-title":"Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus","volume":"50","author":"Baraka","year":"1996","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2017.08.097_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1254\/fpj.122.527","article-title":"Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy","volume":"122","author":"Ikeda","year":"2003","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.bbrc.2017.08.097_bib9","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","article-title":"Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt Axis in breast cancer","volume":"76","author":"Dou","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2017.08.097_bib10","doi-asserted-by":"crossref","first-page":"16222","DOI":"10.1038\/srep16222","article-title":"Modulation of P2X4\/P2X7\/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death","volume":"5","author":"Draganov","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2017.08.097_bib11","first-page":"1","article-title":"The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423","volume":"4","author":"Hashimoto","year":"2010","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.bbrc.2017.08.097_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2016.10.064","article-title":"Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress","volume":"480","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2017.08.097_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.bbrc.2017.08.097_bib14","doi-asserted-by":"crossref","first-page":"e20914","DOI":"10.1371\/journal.pone.0020914","article-title":"Energy metabolism in human pluripotent stem cells and their differentiated counterparts","volume":"6","author":"Varum","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2017.08.097_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"Skrtic","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2017.08.097_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-016-0565-8","article-title":"Choosing the right cell line for renal cell cancer research","volume":"15","author":"Brodaczewska","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2017.08.097_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.15252\/emmm.201404084","article-title":"The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer","volume":"6","author":"Melotti","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbrc.2017.08.097_bib18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.bbabio.2006.05.019","article-title":"Acetyl-L-carnitine feeding to unloaded rats triggers in soleus muscle the coordinated expression of genes involved in mitochondrial biogenesis","volume":"1757","author":"Cassano","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2017.08.097_bib19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jnci\/djn213","article-title":"Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma","volume":"100","author":"Xing","year":"2008","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2017.08.097_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1346-8138.2006.00030.x","article-title":"Crusted scabies in an adult T-cell leukemia\/lymphoma patient successfully treated with oral ivermectin","volume":"33","author":"Yonekura","year":"2006","journal-title":"J.\u00a0Dermatol"},{"key":"10.1016\/j.bbrc.2017.08.097_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(94)91625-X","article-title":"Ivermectin for spasticity in spinal-cord injury","volume":"343","author":"Costa","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2017.08.097_bib22","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood-2010-01-262675","article-title":"The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells","volume":"116","author":"Sharmeen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2017.08.097_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2015.12.059","article-title":"Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2\/STAT5","volume":"469","author":"Xiao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bbrc.2017.08.097_bib24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbrc.2016.02.072","article-title":"Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer","volume":"471","author":"Yu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2017.08.097_bib25","doi-asserted-by":"crossref","first-page":"33769","DOI":"10.18632\/oncotarget.5615","article-title":"Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1731656X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1731656X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T15:50:04Z","timestamp":1574956204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1731656X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0006291X1731656X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.08.097","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.08.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}